Article

Impact of BRAF and MEK Inhibitors on Gingival Hyperplasia in Melanoma Patients

2024-12-04

Abstract excerpt

Although BRAF inhibitors (such as vemurafenib) produce a marked response in patients with advanced melanoma with a BRAF V600 mutation, they eventually develop resistance to this treatment. To address this issue, vemurafenib is increasingly combined with the MEK inhibitor cobimetinib, leading to improved response rates and enhanced survival. However, this treatment modality is associated with numerous side effects....

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 5b81fef4-04b9-5ecb-baf9-739c7966976b
DOI: 10.20944/preprints202412.0171.v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Impact of BRAF and MEK Inhibitors on Gingival Hyperplasia in Melanoma PatientsDOI 10.20944/preprints202412.0171.v1Read

Dermatological adverse events from BRAF inhibitors: a growing problem.Semantic proximity Read

Human papillomavirus-negative epithelial proliferations resembling condylomata acuminata in a patient receiving vemurafenib for Stage IV melanoma.Semantic proximity Read

Cutaneous adverse events to type I BRAF inhibitors: an analysis of effects associated with each inhibitor and therapeutic time interval to onset.Semantic proximity Read

Dramatic response of vemurafenib-induced cutaneous lesions upon switch to dual BRAF/MEK inhibition in a metastatic melanoma patient.Semantic proximity Read

Metastatic melanoma of the oral cavity showing prompt regression with the use of BRAF/MEK inhibitors.Semantic proximity Read

Dermatological approach to vemurafenib skin toxicity: a single centre experience.Semantic proximity Read

Histopathologic characteristics of therapy-associated cutaneous neoplasms with vemurafenib, a selective BRAF kinase inhibitor, used in the treatment of melanoma.Semantic proximity Read

[Management of toxicities of BRAF inhibitors and MEK inhibitors in advanced melanoma].Semantic proximity Read

Acral Malignant Melanoma of the Lower Limb in an Elderly Patient With Diabetes Mellitus and Hypertension: A Case Report From Uganda.Semantic proximity Read

Targeted Therapy with Vemurafenib in Brazilian Children with Refractory Langerhans Cell Histiocytosis: Two Case Reports and a Comprehensive ReviewSemantic proximity Read

[MEK inhibitor-associated retinopathy under binimetinib treatment for cutaneous malignant melanoma].Semantic proximity Read

Nonmalignant cutaneous findings associated with vemurafenib.Semantic proximity Read